Absent and abundant MET immunoreactivity is associated with poor prognosis of patients with oral and oropharyngeal squamous cell carcinoma

• DOI: 10.18632/oncotarget.7534
• Publication Date: 2016-02-20T14:38:50Z
• Authors: Maria J. De Herdt; Stefan M. Willems; Berdine van der S...; Rob Noorlag; Esther I. Verhoef; Geert J.L.H. van ...; Robert J.J. van Es; Senada Koljenović; Robert J. Baatenb...; Leendert H.J. Loo...
• Keywords: Erasmus+

Although the receptor tyrosine kinase (RTK) MET is widely expressed in head and neck squamous cell carcinoma (HNSCC), its prognostic value remains unclear. This might be due to use of a variety antibodies scoring systems. Here, reliability five commercial C-terminal (D1C2, CVD13, SP44, C-12 C-28) was evaluated before examining immunoreactivity HNSCC. Using cancer lines, it shown that D1C2 CVD13 specifically detect under reducing, native formalin-fixed paraffin-embedded (FFPE) conditions. Immunohistochemical staining routinely FFPE oral SCC with demonstrated most sensitive detection membranous MET. Examination 179 oropharyngeal - represented tissue microarray illustrated either uniform (negative or positive) across tumors differs between tumor's center periphery. Ultimately, statistical analysis revealed significantly associated poor 5-year overall disease free survival patients lacking vasoinvasive growth (HR = 3.019, p < 0.001; HR 2.559, 0.001). These findings contribute reliable stratification eligible for treatment biologicals directed against